Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Profound Medical ( (TSE:PRN) ) has issued an announcement.
Profound Medical Corp. reported significant revenue growth for the fourth quarter and full year 2024, with an estimated 105% to 110% increase year-over-year. The company is transitioning its financial reporting to U.S. GAAP and filing with the SEC, aiming to enhance accessibility for U.S.-based investors. This strategic move, alongside a strengthened balance sheet and unique reimbursement status for the TULSA procedure, positions Profound for accelerated growth in the medical device industry.
More about Profound Medical
Profound Medical Corp. is a commercial-stage medical device company specializing in incision-free therapies for tissue ablation. Their primary products include TULSA-PRO, a technology for prostate disease treatment, and Sonalleve, used for treating uterine fibroids and bone metastases, with FDA, CE, and Health Canada approvals.
YTD Price Performance: -3.85%
Average Trading Volume: 9,788
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$329.4M
See more data about PRN stock on TipRanks’ Stock Analysis page.
